- Details
- Description
-
Packaging Size1 Bottle
-
Strength50mg(10ml)
-
CompositonIpilimumab
-
TreatmentMicrosatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) CRC
-
FormInjection
-
Brand达伯欣®
-
Quantity Unit50mg(10ml)*1Bottle/box
-
ManufacturerInnovent Bio,China
About Ipilimumab
Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. Ipilimumab. Fab fragment of ipilimumab (blue) binding CTLA-4 (green).
Colorectal Cancer (CRC)
Indicated in combination with nivolumab for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) CRC
1 mg/kg IV every 3 weeks PLUS nivolumab 240 mg IV every 3 weeks for maximum of 4 doses
Refer to nivolumab prescribing information for continuation as monotherapy